Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Health Services Research|February 15, 2026
Impact of 340B Exposure on Treatment Utilization and Cost for Medicare Patients With CancerDanea M Horn, Kevin SchulmanJournal of Managed Care & Specialty Pharmacy|August 30, 2025
Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer careDanea M Horn, Mireille Jacobson, Kathryn A PhillipsHealth Affairs Scholar|May 12, 2025
Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions: How can the United States harness technological innovation to transform its healthcare system to improve population health outcomes?Robert M Califf, Danea M Horn, Kathryn A PhillipsScience (New York, N.Y.)|April 9, 2026
Diagnostics investments and disease burdenKathryn A Phillips, Danea M Horn, Robert M CaliffJCO Oncology Practice|December 7, 2023
Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?Danea M Horn, Mireille Jacobson, Abby E Alpert, et al.JCO Oncology Practice|January 13, 2023
Biosimilar Competition and Payments in Medicare: The Case of TrastuzumabDanea M Horn, Abby E Alpert, Mark G Duggan, et al.Pageof 1